Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Update

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 81,000 shares, a decrease of 48.1% from the March 31st total of 156,200 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 69,200 shares, the days-to-cover ratio is presently 1.2 days.

Sensei Biotherapeutics Stock Up 2.0 %

Sensei Biotherapeutics stock traded up $0.02 during midday trading on Friday, hitting $1.02. 6,161 shares of the company’s stock were exchanged, compared to its average volume of 92,672. The company has a quick ratio of 11.92, a current ratio of 11.92 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average of $0.97 and a two-hundred day moving average of $0.81. Sensei Biotherapeutics has a 12 month low of $0.51 and a 12 month high of $1.72.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. On average, equities research analysts forecast that Sensei Biotherapeutics will post -0.97 EPS for the current year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.